Thymoglobulin Capping Defects Cited In Aventis Pasteur Warning Letter
This article was originally published in The Pink Sheet Daily
FDA cites Genzyme’s Thymoglobulin contract manufacturer Aventis Pasteur for failures related to its quality control unit. Warning letter also points to quality control deficiencies involving haemophilius b conjugate vaccine and rabies vaccine.
You may also be interested in...
The proposal is an effort to win FTC approval for Genzyme's $1 bil. bid for Ilex. Genzyme expects to issue 22 mil. shares as part of the deal, but the dilution may be offset by stronger than previously expected performance of Renagel, Fabrazyme and Cerezyme.
Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.
The four-pronged plan will address “bio-burden,” manufacturing techniques, quality systems and execution, CEO Pien says. Chiron has met twice with U.K. authorities and hopes to realize similar progress with FDA soon.